Acute high-dose MitoQ does not increase urinary kidney injury markers in healthy adults: a randomized crossover trial
Braxton A. Linder, Nina L. Stute, Zach J. Hutchison, Alex M. Barnett, McKenna A. Tharpe, Andreas N. Kavazis, Danielle L. Kirkman, Orlando M. Gutiérrez, Austin T. Robinson
Abstract
We found acute high-dose mitochondria-targeted antioxidant (MitoQ) supplementation was not nephrotoxic and had no effect on markers of acute kidney injury in healthy adults. These findings can help bolster further confidence in the safety of MitoQ, particularly for future investigations seeking to examine the role of mitochondrial oxidative stress, via acute MitoQ supplementation, on various physiological outcomes.
Topics & Concepts
Oxidative stressMedicineAcute kidney injuryCrossover studyNephrotoxicityRandomized controlled trialConfidence intervalInternal medicineKidneyPharmacologyPlaceboPathologyAlternative medicineAcute Kidney Injury ResearchMitochondrial Function and PathologyDialysis and Renal Disease Management